Role of cetrorelix in the prevention and treatment of ovarian hyperstimulation syndrome: A prospective case control study

Abstract

Because of its terrible effects, ovarian hyperstimulation syndrome (OHSS) has long piqued the interest of medical professionals. Since the syndrome is an iatrogenic condition brought on by elective ovarian stimulation in the pursuit of pregnancy, its complete prevention is imperative. The gonadotropin releasing hormone (GnRH) antagonist Cetrorelix has been shown in some studies to be beneficial in the prevention of OHSS as well as an effective treatment for the condition. Therefore, we created a study at a hospital to find out how Cetrorelix works to prevent and treat OHSS in patients undergoing long and short protocols for those undergoing embryo transfer and in-vitro fertilization (IVF–ET) who are susceptible to the illness.The study includes 102 patients undergoing COS for IVF in total. To stimulate each case, a long and a short protocol were employed. Depending on whether a GnRH antagonist was administered following ovum pick-up (OPU), the patients were split into two groups: the control group (n = 51) and the Cetrorelix (antagonist) group (n = 51). Beginning on the day of ovum pickup, the study group received five days' worth of Cetrorelix 0.25 mg.: While the antagonist group had a significantly higher moderate OHSS incidence (p=0.01), the incidence between mild and severe OHSS was considerably reduced(p<0.05). Not a single patient experienced critical OHSS. OHSS can be prevented and treated effectively by administering the GnRH antagonist Cetrorelix to patients undergoing either a long- or short-term protocol during the early luteal phase.